Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates

PA Bradford, AA Miller, J O'Donnell… - ACS infectious …, 2020 - ACS Publications
The Centers for Disease Control and the World Health Organization have issued a list of
priority pathogens for which there are dwindling therapeutic options, including antibiotic …

Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber …

S Jacobsson, D Golparian, J Oxelbark… - Frontiers in …, 2021 - frontiersin.org
Antimicrobial resistance in Neisseria gonorrhoeae is threatening the treatment and control of
gonorrhea globally, and new treatment options are imperative. Utilizing our dynamic in vitro …

Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a …

S Jacobsson, D Golparian, J Oxelbark… - Frontiers in …, 2022 - frontiersin.org
Novel antimicrobials for effective treatment of uncomplicated gonorrhea are essential, and
the first-in-class, oral spiropyrimidinetrione DNA gyrase B inhibitor zoliflodacin appears …

High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a …

S Jacobsson, D Golparian, RA Alm… - Antimicrobial agents …, 2014 - Am Soc Microbiol
We evaluated the activity of the novel spiropyrimidinetrione AZD0914 (DNA gyrase inhibitor)
against clinical gonococcal isolates and international reference strains (n= 250), including …

[HTML][HTML] Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea

SN Taylor, J Marrazzo, BE Batteiger… - … England Journal of …, 2018 - Mass Medical Soc
Abstract Background Antibiotic-resistant Neisseria gonorrhoeae has prompted the
development of new therapies. Zoliflodacin is a new antibiotic that inhibits DNA …

High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European …

M Unemo, J Ahlstrand, L Sánchez-Busó… - Journal of …, 2021 - academic.oup.com
Objectives Novel antimicrobials for treatment of gonorrhoea are imperative. The first-in-class
spiropyrimidinetrione zoliflodacin is promising and currently in an international Phase 3 …

In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical Neisseria gonorrhoeae Isolates and International Reference …

D Golparian, P Fernandes, M Ohnishi… - Antimicrobial agents …, 2012 - Am Soc Microbiol
Gonorrhea may become untreatable, and new treatment options are essential. We
investigated the in vitro activity of the first fluoroketolide, solithromycin. Clinical Neisseria …

Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae

RA Alm, SD Lahiri, A Kutschke… - Antimicrobial agents …, 2015 - Am Soc Microbiol
The unmet medical need for novel intervention strategies to treat Neisseria gonorrhoeae
infections is significant and increasing, as rapidly emerging resistance in this pathogen is …

Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea

M Unemo, D Golparian, DW Eyre - Neisseria gonorrhoeae: methods and …, 2019 - Springer
Gonorrhea and antimicrobial resistance (AMR) in Neisseria gonorrhoeae are major public
health concerns globally. Dual antimicrobial therapy (mainly ceftriaxone 250–500 mg× 1 …

A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea

EW Hook III, M Golden, BD Jamieson… - Clinical infectious …, 2015 - academic.oup.com
Background. Progressive resistance to antimicrobial agents has reduced options for
gonorrhea therapy worldwide. Solithromycin (CEM-101) is a novel oral fluoroketolide …